Inhibitor |
IC50 (μM) |
Ki (μM) |
Substrate used |
Cell System |
Reference |
(-)-Zearalenone |
24.8 |
|
Tetraethylammonium1 |
S2 cells |
Tachampa, 2008 |
1-ethylpyridinium chloride (EtPy-Cl) |
36.7 |
|
Tetraethylammonium1 |
CHO-OCT2 |
Cheng, 2011 |
1-hexylpyridinium chloride (HePy-Cl) |
0.35 |
|
Tetraethylammonium1 |
CHO-OCT2 |
Cheng, 2011 |
1-methyl-3-butylimidazolium chloride (Bmim-Cl) |
1.5 |
|
Tetraethylammonium1 |
CHO-OCT2 |
Cheng, 2011 |
1-methyl-4-phenylpyridinium (MPP+) |
7 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Severance, 2017 |
1-methyl-4-phenylpyridinium (MPP+) |
3 |
|
NBD-MTMA |
CHO-OCT2 |
Belzer, 2013 |
3,4-methylenedioxymetamphetamine (MDMA) |
|
1.63 |
N-methylpyridinium |
HEK293-OCT2 |
Amphoux, 2006 |
Aconitine |
59.2 |
145.6 |
Tetraethylammonium1 |
S2-OCT2 |
Chiba, 2013 |
Aflatoxin B1 |
121 |
|
Tetraethylammonium1 |
S2 cells |
Tachampa, 2008 |
Allethrin |
42.6 |
|
Rhodamine 123 |
HEK293 cells |
Chedik, 2017 |
Alpha-zearalenol |
34.3 |
|
Tetraethylammonium1 |
S2 cells |
Tachampa, 2008 |
Amantadine |
51 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Sandoval, 2018 |
Amantadine |
10.1 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
CHO-OCT2 |
Sandoval, 2018 |
Amantadine |
27.1 |
|
Metformin1,3 |
CHO-OCT2 |
Sandoval, 2018 |
Amantadine |
|
28.4 |
N-methylpyridinium |
HEK293-OCT2 |
Amphoux, 2006 |
Amantadine |
24.5 |
|
NBD-MTMA |
CHO-OCT2 |
Sandoval, 2018 |
Amantadine |
32.1 |
|
Tetraethylammonium1 |
CHO-OCT2 |
Sandoval, 2018 |
Amantadine |
45.9 |
|
YM155 |
HEK293-OCT2 |
Minematsu, 2010 |
Amitriptyline |
11.3 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Sandoval, 2018 |
Amitriptyline |
1.8 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
CHO-OCT2 |
Sandoval, 2018 |
Amitriptyline |
0.51 |
|
Metformin1,3 |
HEK293-OCT2 |
Hacker, 2015 |
Amitriptyline |
2.4 |
|
Metformin1,3 |
CHO-OCT2 |
Sandoval, 2018 |
Amitriptyline |
14 |
|
N-methylpyridinium |
HEK293-OCT2 |
Zolk, 2009 |
Amitriptyline |
2.5 |
|
NBD-MTMA |
CHO-OCT2 |
Belzer, 2013 |
Amitriptyline |
4 |
|
NBD-MTMA |
CHO-OCT2 |
Sandoval, 2018 |
Amitriptyline |
2.4 |
2.5 |
Tetraethylammonium1 |
S2-OCT2 |
Chiba, 2013 |
Amitriptyline |
5 |
|
Tetraethylammonium1 |
CHO-OCT2 |
Sandoval, 2018 |
Amodiaquine |
11 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
van, 2017 |
Amphetamine |
20.3 |
|
Metformin1,3 |
HEK293-OCT2 |
Wagner, 2017 |
Anastrozole |
327.6 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Sandoval, 2018 |
Anastrozole |
39.2 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
CHO-OCT2 |
Sandoval, 2018 |
Anastrozole |
51.1 |
|
Metformin1,3 |
CHO-OCT2 |
Sandoval, 2018 |
Anastrozole |
86 |
|
NBD-MTMA |
CHO-OCT2 |
Sandoval, 2018 |
Anastrozole |
113.4 |
|
Tetraethylammonium1 |
CHO-OCT2 |
Sandoval, 2018 |
Anisodine |
139.6 |
|
1-methyl-4-phenylpyridinium (MPP+) |
HEK293-OCT2 |
Chen, 2019 |
Atomoxetine |
20.4 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Sandoval, 2018 |
Atomoxetine |
3.5 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
CHO-OCT2 |
Sandoval, 2018 |
Atomoxetine |
6.6 |
|
Metformin1,3 |
CHO-OCT2 |
Sandoval, 2018 |
Atomoxetine |
7.6 |
|
NBD-MTMA |
CHO-OCT2 |
Sandoval, 2018 |
Atomoxetine |
12.8 |
|
Tetraethylammonium1 |
CHO-OCT2 |
Sandoval, 2018 |
Atropine |
12.4 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Sandoval, 2018 |
Atropine |
1.4 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
CHO-OCT2 |
Sandoval, 2018 |
Atropine |
1.3 |
|
Metformin1,3 |
CHO-OCT2 |
Sandoval, 2018 |
Atropine |
39 |
|
N-methylpyridinium |
HEK293-OCT2 |
Muller, 2005 |
Atropine |
2.3 |
|
NBD-MTMA |
CHO-OCT2 |
Sandoval, 2018 |
Atropine |
2 |
2.4 |
Tetraethylammonium1 |
S2-OCT2 |
Chiba, 2013 |
Atropine |
3.4 |
|
Tetraethylammonium1 |
CHO-OCT2 |
Sandoval, 2018 |
Benztropine |
13.4 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Sandoval, 2018 |
Benztropine |
0.3 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
CHO-OCT2 |
Sandoval, 2018 |
Benztropine |
0.4 |
|
Metformin1,3 |
CHO-OCT2 |
Sandoval, 2018 |
Benztropine |
0.8 |
|
NBD-MTMA |
CHO-OCT2 |
Sandoval, 2018 |
Benztropine |
1 |
|
Tetraethylammonium1 |
CHO-OCT2 |
Sandoval, 2018 |
Berberine |
8 |
|
1-methyl-4-phenylpyridinium (MPP+) |
MDCK-OCT2 |
Sun, 2014 |
Berberine |
0.438 |
|
Norepinephrine |
MDCK-OCT2 |
Sun, 2014 |
Berberine |
0.371 |
|
Serotonin |
MDCK-OCT2 |
Sun, 2014 |
Bithionol |
1.9 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
Bupropion |
32.2 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Sandoval, 2018 |
Bupropion |
11.1 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
CHO-OCT2 |
Sandoval, 2018 |
Bupropion |
8.6 |
|
Metformin1,3 |
CHO-OCT2 |
Sandoval, 2018 |
Bupropion |
10.8 |
|
NBD-MTMA |
CHO-OCT2 |
Sandoval, 2018 |
Bupropion |
13.4 |
|
Tetraethylammonium1 |
CHO-OCT2 |
Sandoval, 2018 |
Buspirone |
68.5 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Sandoval, 2018 |
Buspirone |
12 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
Buspirone |
8.6 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
CHO-OCT2 |
Sandoval, 2018 |
Buspirone |
10.2 |
|
Metformin1,3 |
CHO-OCT2 |
Sandoval, 2018 |
Buspirone |
19.6 |
|
NBD-MTMA |
CHO-OCT2 |
Sandoval, 2018 |
Buspirone |
19.8 |
|
Tetraethylammonium1 |
CHO-OCT2 |
Sandoval, 2018 |
Butylscopolamine |
764 |
|
N-methylpyridinium |
HEK293-OCT2 |
Muller, 2005 |
Camostat |
16.5 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
Carvedilol |
55.2 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Belzer, 2013 |
Carvedilol |
63 |
|
N-methylpyridinium |
HEK293-OCT2 |
Zolk, 2009 |
Carvedilol |
13.1 |
|
NBD-MTMA |
CHO-OCT2 |
Belzer, 2013 |
Cetirizine |
ND |
|
Tetraethylammonium1 |
OCT2-expressing oocytes |
Tsuruoka, 2006 |
Chelerythrine |
10.8 |
|
1-methyl-4-phenylpyridinium (MPP+) |
OCT2 |
Shams, 2018 |
Chlorhexidine |
0.4 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
Chloroquine |
129 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Belzer, 2013 |
Chloroquine |
9.6 |
|
Metformin1,3 |
CHO-OCT2 |
Belzer, 2013 |
Chloroquine |
1096 |
|
N-methylpyridinium |
HEK293-OCT2 |
Zolk, 2009 |
Chloroquine |
117 |
|
NBD-MTMA |
CHO-OCT2 |
Belzer, 2013 |
Chlorpromazine |
14 |
|
N-methylpyridinium |
HEK293-OCT2 |
Zolk, 2009 |
Chlorpromazine |
2.6 |
|
NBD-MTMA |
CHO-OCT2 |
Belzer, 2013 |
Chlorpyrifos |
20.7 |
24.8 |
Tetraethylammonium1 |
S2-OCT2 |
Chiba, 2013 |
Choline |
435 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Severance, 2017 |
Cimetidine2 |
|
146 |
1-methyl-4-phenylpyridinium (MPP+) |
HEK293-OCT2 |
Ito, 2012 |
Cimetidine2 |
171 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Belzer, 2013 |
Cimetidine2 |
113 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Severance, 2017 |
Cimetidine2 |
|
104 |
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Ito, 2012 |
Cimetidine2 |
|
95 |
m-iodobenzylguanidine (MIBG) |
HEK293-OCT2 |
Ito, 2012 |
Cimetidine2 |
|
124 |
Metformin1,3 |
HEK293-OCT2 |
Ito, 2012 |
Cimetidine2 |
25.4 |
|
Metformin1,3 |
CHO-OCT2 |
Belzer, 2013 |
Cimetidine2 |
120 |
|
N-methylpyridinium |
HEK293-OCT2 |
Zolk, 2009 |
Cimetidine2 |
70.4 |
|
NBD-MTMA |
CHO-OCT2 |
Belzer, 2013 |
Cimetidine2 |
111.5 |
|
Para-Aminosalicylic acid (PAS) |
HEK293-OCT2 |
Parvez, 2017 |
Cimetidine2 |
373 |
|
Tetraethylammonium1 |
OCT2-expressing oocytes |
Okuda, 1999 |
Cimetidine2 |
|
144 |
Tetraethylammonium1 |
HEK293-OCT2 |
Ito, 2012 |
Cimetidine2 |
110 |
|
YM155 |
HEK293-OCT2 |
Minematsu, 2010 |
Citreoviridin A |
17.7 |
|
Tetraethylammonium1 |
S2 cells |
Tachampa, 2008 |
Clonidine |
6 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Belzer, 2013 |
Clonidine |
0.68 |
|
Metformin1,3 |
CHO-OCT2 |
Belzer, 2013 |
Clonidine |
23 |
|
N-methylpyridinium |
HEK293-OCT2 |
Muller, 2005 |
Clonidine |
16 |
|
N-methylpyridinium |
HEK293-OCT2 |
Zolk, 2009 |
Clonidine |
4.5 |
|
NBD-MTMA |
CHO-OCT2 |
Belzer, 2013 |
Cocaine |
|
113 |
N-methylpyridinium |
HEK293-OCT2 |
Amphoux, 2006 |
Corticosterone |
6.7 |
9.1 |
Tetraethylammonium1 |
S2-OCT2 |
Chiba, 2013 |
Corticosterone |
5.35 |
|
YM155 |
HEK293-OCT2 |
Minematsu, 2010 |
Creatinine |
580 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Ciarimboli, 2012 |
D-amphetamine |
|
10.5 |
N-methylpyridinium |
HEK293-OCT2 |
Amphoux, 2006 |
Decynium-22 |
0.0014 |
|
1-methyl-4-phenylpyridinium (MPP+) |
MDCK-OCT2 |
Sun, 2014 |
Decynium-22 |
0.005 |
|
Norepinephrine |
MDCK-OCT2 |
Sun, 2014 |
Decynium-22 |
0.0012 |
|
Serotonin |
MDCK-OCT2 |
Sun, 2014 |
Decynium-22 |
|
0.1 |
Tetraethylammonium1 |
OCT2-expressing oocytes |
Gorboulev, 1997 |
Decynium-22 |
13.8 |
|
Tetraethylammonium1 |
OCT2-expressing oocytes |
Okuda, 1999 |
Desipramine |
16 |
|
Tetraethylammonium1 |
OCT2-expressing oocytes |
Gorboulev, 1997 |
Desloratadine |
60 |
|
N-methylpyridinium |
HEK293-OCT2 |
Zolk, 2009 |
Diazepam |
32.3 |
|
Tetraethylammonium1 |
S2-OCT2 |
Chiba, 2013 |
Dihydroergotamine |
49.9 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
Diphenhydramine |
15 |
|
N-methylpyridinium |
HEK293-OCT2 |
Muller, 2005 |
Diphenhydramine |
21 |
|
N-methylpyridinium |
HEK293-OCT2 |
Zolk, 2009 |
Diphenhydramine |
5.8 |
|
NBD-MTMA |
CHO-OCT2 |
Belzer, 2013 |
Diphenidol |
34.3 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Severance, 2017 |
Disopyramide |
324 |
|
N-methylpyridinium |
HEK293-OCT2 |
Zolk, 2009 |
Disopyramide |
39 |
|
NBD-MTMA |
CHO-OCT2 |
Belzer, 2013 |
Dolutegravir |
1.9 |
|
Metformin1,3 |
MDCKII_OCT2 |
Reese, 2013 |
Domperidone |
7.9 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
Doravirine |
67 |
|
Metformin1,3 |
CHO-K1-OCT2 |
Bleasby, 2019 |
Doxepin |
0.25 |
|
Metformin1,3 |
HEK293-OCT2 |
Hacker, 2015 |
Doxepin |
13 |
|
N-methylpyridinium |
HEK293-OCT2 |
Zolk, 2009 |
Doxepin |
1.5 |
|
NBD-MTMA |
CHO-OCT2 |
Belzer, 2013 |
DX-619 |
|
0.94 |
Creatinine |
S2-OCT2 |
Imamura, 2011 |
Efavirenz |
5.66 |
|
Metformin1,3 |
MDCK-OCT2 |
Ceckova, 2018 |
Epinastine |
4.3 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
Ethambutol |
229 |
|
1-methyl-4-phenylpyridinium (MPP+) |
HEK293-OCT2 |
Parvez, 2016 |
Ethambutol |
189.2 |
|
Metformin1,3 |
HEK293-OCT2 |
Parvez, 2016 |
Ethidium |
0.8 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Severance, 2017 |
Ethinyl estradiol |
2.2 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
Ethylacridinium |
0.08 |
|
NBD-MTMA |
CHO-OCT2 |
Belzer, 2013 |
Etilefrine |
4009 |
|
N-methylpyridinium |
HEK293-OCT2 |
Muller, 2005 |
Famotidine |
36.1 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
Famotidine |
114 |
|
N-methylpyridinium |
OCT2-expressing oocytes |
Bourdet, 2005 |
Fampridine |
66.8 |
|
Metformin1,3 |
HEK293-OCT2 |
Xiao, 2018 |
Fenamiphos |
2.8 |
|
Dopamine |
HEK293 cells |
Chedik, 2019 |
Fenamiphos |
6.9 |
|
Rhodamine 123 |
HEK293 cells |
Chedik, 2019 |
Fenfluramine |
10 |
|
N-methylpyridinium |
HEK293-OCT2 |
Zolk, 2009 |
Fenitrothion |
13.2 |
16.9 |
Tetraethylammonium1 |
S2-OCT2 |
Chiba, 2013 |
Flecainide |
191 |
|
N-methylpyridinium |
HEK293-OCT2 |
Zolk, 2009 |
Flecainide |
234 |
|
NBD-MTMA |
CHO-OCT2 |
Belzer, 2013 |
Fluoxetine |
56.7 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Sandoval, 2018 |
Fluoxetine |
16.7 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
CHO-OCT2 |
Sandoval, 2018 |
Fluoxetine |
18.6 |
|
Metformin1,3 |
CHO-OCT2 |
Sandoval, 2018 |
Fluoxetine |
20.1 |
|
NBD-MTMA |
CHO-OCT2 |
Sandoval, 2018 |
Fluoxetine |
36 |
|
Tetraethylammonium1 |
CHO-OCT2 |
Sandoval, 2018 |
Flurazepam |
60 |
|
N-methylpyridinium |
HEK293-OCT2 |
Zolk, 2009 |
Furamidine |
182 |
|
N-methylpyridinium |
CHO-OCT2 |
Ming, 2009 |
Gabexate |
0.9 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
Gliotoxin |
117 |
|
Tetraethylammonium1 |
S2 cells |
Tachampa, 2008 |
Granisetron |
4.3 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
Grepafloxacin |
|
10.4 |
Creatinine |
S2-OCT2 |
Imamura, 2011 |
Haloperidol |
32.5 |
51.6 |
Tetraethylammonium1 |
S2-OCT2 |
Chiba, 2013 |
Imatinib |
4.2 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
Imatinib |
6.7 |
|
Creatinine |
HEK293-OCT2 |
Tanihara, 2009 |
Imipramine |
3.9 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Belzer, 2013 |
Imipramine |
28.9 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Severance, 2017 |
Imipramine |
4.9 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Sandoval, 2018 |
Imipramine |
0.5 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
CHO-OCT2 |
Sandoval, 2018 |
Imipramine |
0.77 |
|
Metformin1,3 |
CHO-OCT2 |
Belzer, 2013 |
Imipramine |
0.4 |
|
Metformin1,3 |
CHO-OCT2 |
Sandoval, 2018 |
Imipramine |
6 |
|
N-methylpyridinium |
HEK293-OCT2 |
Zolk, 2009 |
Imipramine |
1.4 |
|
NBD-MTMA |
CHO-OCT2 |
Belzer, 2013 |
Imipramine |
1.4 |
|
NBD-MTMA |
CHO-OCT2 |
Sandoval, 2018 |
Imipramine |
1.3 |
|
Tetraethylammonium1 |
CHO-OCT2 |
Sandoval, 2018 |
Indinavir |
142 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
Ipratropium |
15 |
|
N-methylpyridinium |
HEK293-OCT2 |
Zolk, 2009 |
Ipratropium |
0.17 |
|
NBD-MTMA |
CHO-OCT2 |
Belzer, 2013 |
Irinotecan |
15.6 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Sandoval, 2018 |
Irinotecan |
2.7 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
Irinotecan |
1.7 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
CHO-OCT2 |
Sandoval, 2018 |
Irinotecan |
3.3 |
|
Metformin1,3 |
CHO-OCT2 |
Sandoval, 2018 |
Irinotecan |
3.2 |
|
NBD-MTMA |
CHO-OCT2 |
Sandoval, 2018 |
Irinotecan |
4.5 |
|
Tetraethylammonium1 |
CHO-OCT2 |
Sandoval, 2018 |
Ketamine |
|
22.7 |
N-methylpyridinium |
HEK293-OCT2 |
Amphoux, 2006 |
Lansoprazole |
9.5 |
|
Metformin1,3 |
HEK293-OCT2 |
Nies, 2011 |
Lansoprazole |
3.28 |
|
Metformin1,3 |
HEK293-OCT2 |
Hacker, 2015 |
Lansoprazole |
13 |
|
Para-Aminosalicylic acid (PAS) |
HEK293-OCT2 |
Parvez, 2017 |
Leucomycin |
182 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
Levomethadone |
60 |
|
N-methylpyridinium |
HEK293-OCT2 |
Zolk, 2009 |
Lidocaine |
104.6 |
86.8 |
Tetraethylammonium1 |
S2-OCT2 |
Chiba, 2013 |
Linagliptin |
80 |
|
Metformin1,3 |
HEK293-OCT2 |
Ishiguro, 2013 |
Malathion |
71.1 |
|
Tetraethylammonium1 |
S2-OCT2 |
Chiba, 2013 |
Mefloquine |
204 |
|
N-methylpyridinium |
HEK293-OCT2 |
Zolk, 2009 |
Memantine |
|
7.3 |
N-methylpyridinium |
HEK293-OCT2 |
Amphoux, 2006 |
Mepiperphenidol |
4.8 |
|
Tetraethylammonium1 |
OCT2-expressing oocytes |
Gorboulev, 1997 |
Mepiperphenidol |
|
4.8 |
Tetraethylammonium1 |
OCT2-expressing oocytes |
Gorboulev, 1997 |
Metformin1,3 |
566 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Belzer, 2013 |
Metformin1,3 |
223 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Severance, 2017 |
Metformin1,3 |
521 |
|
N-methylpyridinium |
OCT2-expressing oocytes |
Bourdet, 2005 |
Metformin1,3 |
|
289 |
N-methylpyridinium |
HEK293-OCT2 |
Umehara, 2007 |
Metformin1,3 |
398 |
|
N-methylpyridinium |
HEK293-OCT2 |
Zolk, 2009 |
Metformin1,3 |
1180 |
|
NBD-MTMA |
CHO-OCT2 |
Belzer, 2013 |
Metformin1,3 |
125.6 |
|
Para-Aminosalicylic acid (PAS) |
HEK293-OCT2 |
Parvez, 2017 |
Metformin1,3 |
|
1380 |
Tetraethylammonium1 |
HEK293-OCT2 |
Umehara, 2007 |
Methamphetamine |
15 |
|
Metformin1,3 |
HEK293-OCT2 |
Wagner, 2017 |
Mexiletine |
50.4 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Sandoval, 2018 |
Mexiletine |
19.4 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
CHO-OCT2 |
Sandoval, 2018 |
Mexiletine |
21.5 |
|
Metformin1,3 |
CHO-OCT2 |
Sandoval, 2018 |
Mexiletine |
55 |
|
N-methylpyridinium |
HEK293-OCT2 |
Zolk, 2009 |
Mexiletine |
30.5 |
|
NBD-MTMA |
CHO-OCT2 |
Sandoval, 2018 |
Mexiletine |
28.5 |
|
Tetraethylammonium1 |
CHO-OCT2 |
Sandoval, 2018 |
Mianserin |
17.7 |
|
Tetraethylammonium1 |
S2-OCT2 |
Chiba, 2013 |
Mitoxantrone |
73.3 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
MK-801 |
|
21.5 |
N-methylpyridinium |
HEK293-OCT2 |
Amphoux, 2006 |
Monocrotaline |
1852.6 |
|
1-methyl-4-phenylpyridinium (MPP+) |
HEK293-OCT2 |
Chen, 2019 |
N-butyl-N-methylpyrrolidinium chloride (BmPy-Cl) |
0.48 |
|
Tetraethylammonium1 |
CHO-OCT2 |
Cheng, 2011 |
N-butylpyridinium chloride (NBuPy-Cl) |
2.29 |
|
Tetraethylammonium1 |
CHO-OCT2 |
Cheng, 2011 |
N-methylpyridinium |
|
2.4 |
Tetraethylammonium1 |
OCT2-expressing oocytes |
Gorboulev, 1997 |
N-methylpyridinium |
4.42 |
|
YM155 |
HEK293-OCT2 |
Minematsu, 2010 |
Naloxone |
235.7 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Sandoval, 2018 |
Naloxone |
20.3 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
CHO-OCT2 |
Sandoval, 2018 |
Naloxone |
29.5 |
|
Metformin1,3 |
CHO-OCT2 |
Sandoval, 2018 |
Naloxone |
55.1 |
|
NBD-MTMA |
CHO-OCT2 |
Sandoval, 2018 |
Naloxone |
67.3 |
|
Tetraethylammonium1 |
CHO-OCT2 |
Sandoval, 2018 |
NBD-MTMA |
46 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Severance, 2017 |
Nicotine |
52.8 |
57.7 |
Tetraethylammonium1 |
S2-OCT2 |
Chiba, 2013 |
Nifekalant |
10.3 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
Olaparib |
19.9 |
|
1-methyl-4-phenylpyridinium (MPP+) |
HEK293-OCT2 |
McCormick, 2017 |
Omeprazole |
6.7 |
|
Metformin1,3 |
HEK293-OCT2 |
Nies, 2011 |
Omeprazole |
5.53 |
|
Para-Aminosalicylic acid (PAS) |
HEK293-OCT2 |
Parvez, 2017 |
Ondansetron |
1.7 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
Ondansetron |
|
85 |
Metformin1,3 |
HEK293-OCT2 |
Li, 2013 |
P-hydroxymethamphetamine (P-OHMA) |
83.8 |
|
Metformin1,3 |
HEK293-OCT2 |
Wagner, 2017 |
Pantoprazole |
1.5 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
Pantoprazole |
2.8 |
|
Metformin1,3 |
HEK293-OCT2 |
Nies, 2011 |
Pantoprazole |
0.56 |
|
Metformin1,3 |
HEK293-OCT2 |
Hacker, 2015 |
Para-Aminosalicylic acid (PAS) |
94.2 |
|
1-methyl-4-phenylpyridinium (MPP+) |
HEK293-OCT2 |
Parvez, 2016 |
Para-Aminosalicylic acid (PAS) |
85.8 |
|
Metformin1,3 |
HEK293-OCT2 |
Parvez, 2016 |
Pazopanib |
3.5 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Sauzay, 2016 |
Pentamidine |
1.2 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
Pentamidine |
10.6 |
|
N-methylpyridinium |
CHO-OCT2 |
Ming, 2009 |
Phenanthriplatin |
2 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Hucke, 2018 |
Phencyclidine |
|
24.9 |
N-methylpyridinium |
HEK293-OCT2 |
Amphoux, 2006 |
Phenformin |
|
54 |
N-methylpyridinium |
HEK293-OCT2 |
Umehara, 2007 |
Phenformin |
|
111 |
Tetraethylammonium1 |
HEK293-OCT2 |
Umehara, 2007 |
Phenoxybenzamine |
4.9 |
|
N-methylpyridinium |
HEK293-OCT2 |
Hayer-Zillgen, 2002 |
Phosmet |
3.6 |
|
Dopamine |
HEK293 cells |
Chedik, 2019 |
Phosmet |
7.9 |
|
Rhodamine 123 |
HEK293 cells |
Chedik, 2019 |
Pilocarpine |
109.3 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Sandoval, 2018 |
Pilocarpine |
55.7 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
CHO-OCT2 |
Sandoval, 2018 |
Pilocarpine |
34.5 |
|
Metformin1,3 |
CHO-OCT2 |
Sandoval, 2018 |
Pilocarpine |
48.2 |
|
NBD-MTMA |
CHO-OCT2 |
Sandoval, 2018 |
Pilocarpine |
61.9 |
|
Tetraethylammonium1 |
CHO-OCT2 |
Sandoval, 2018 |
Pilsicainide |
ND |
|
Tetraethylammonium1 |
OCT2-expressing oocytes |
Tsuruoka, 2006 |
Prazosin |
13.6 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
Prazosin |
80.4 |
|
YM155 |
HEK293-OCT2 |
Minematsu, 2010 |
Procainamide |
|
50 |
Tetraethylammonium1 |
OCT2-expressing oocytes |
Gorboulev, 1997 |
Procainamide |
91.9 |
|
YM155 |
HEK293-OCT2 |
Minematsu, 2010 |
Proguanil |
13 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
van, 2017 |
Propafenone |
25 |
|
N-methylpyridinium |
HEK293-OCT2 |
Zolk, 2009 |
Propafenone |
3.6 |
|
NBD-MTMA |
CHO-OCT2 |
Belzer, 2013 |
Propamocarb |
38.1 |
|
4-DiASP |
HEK293 cells |
Gueniche, 2020 |
Propranolol |
71.6 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Belzer, 2013 |
Propranolol |
229 |
|
N-methylpyridinium |
HEK293-OCT2 |
Zolk, 2009 |
Propranolol |
67.2 |
|
NBD-MTMA |
CHO-OCT2 |
Belzer, 2013 |
Pyridine |
790 |
|
Tetraethylammonium1 |
CHO-OCT2 |
Cheng, 2011 |
Pyrimethamine |
23.6 |
|
1-methyl-4-phenylpyridinium (MPP+) |
HEK293-OCT2 |
Shen, 2013 |
Pyrimethamine |
1.6 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
van, 2017 |
Pyrimethamine |
4.8 |
|
Metformin1,3 |
HEK293-OCT2 |
Shen, 2013 |
Quinidine |
91.6 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Belzer, 2013 |
Quinidine |
92.6 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Severance, 2017 |
Quinidine |
91.1 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Sandoval, 2018 |
Quinidine |
6.4 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
CHO-OCT2 |
Sandoval, 2018 |
Quinidine |
6.4 |
|
Metformin1,3 |
CHO-OCT2 |
Belzer, 2013 |
Quinidine |
18.6 |
|
Metformin1,3 |
CHO-OCT2 |
Sandoval, 2018 |
Quinidine |
8.7 |
|
N-methylpyridinium |
OCT2-expressing oocytes |
Bourdet, 2005 |
Quinidine |
13.3 |
|
N-methylpyridinium |
CHO-OCT2 |
Ming, 2009 |
Quinidine |
87 |
|
N-methylpyridinium |
HEK293-OCT2 |
Zolk, 2009 |
Quinidine |
29.6 |
|
NBD-MTMA |
CHO-OCT2 |
Belzer, 2013 |
Quinidine |
18.7 |
|
NBD-MTMA |
CHO-OCT2 |
Sandoval, 2018 |
Quinidine |
10.7 |
|
Para-Aminosalicylic acid (PAS) |
HEK293-OCT2 |
Parvez, 2017 |
Quinidine |
23.6 |
|
Tetraethylammonium1 |
CHO-OCT2 |
Sandoval, 2018 |
Quinidine |
11 |
|
YM155 |
HEK293-OCT2 |
Minematsu, 2010 |
Quinine |
3.4 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
van, 2017 |
Quinine |
23 |
|
N-methylpyridinium |
HEK293-OCT2 |
Muller, 2005 |
Quinine |
|
3.4 |
Tetraethylammonium1 |
OCT2-expressing oocytes |
Gorboulev, 1997 |
Rabeprazole |
5.7 |
|
Metformin1,3 |
HEK293-OCT2 |
Nies, 2011 |
Ranitidine |
|
79 |
Cimetidine2 |
HEK293-OCT2 |
Tahara, 2005 |
Ranitidine |
|
30.5 |
Famotidine |
HEK293-OCT2 |
Tahara, 2005 |
Ranitidine |
76 |
|
N-methylpyridinium |
OCT2-expressing oocytes |
Bourdet, 2005 |
Ranitidine |
1617 |
|
N-methylpyridinium |
HEK293-OCT2 |
Muller, 2005 |
Ranitidine |
482 |
|
Trospium |
HEK293-OCT2 |
Abebe, 2020 |
Rimantadine |
4.4 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
Ritonavir |
24.8 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
Rucaparib |
31 |
|
Metformin1,3 |
CHO-OCT2 |
Liao, 2020 |
Sibutramine |
29 |
|
N-methylpyridinium |
HEK293-OCT2 |
Zolk, 2009 |
Sitagliptin |
7.41 |
|
Metformin1,3 |
HEK293-OCT2 |
Hacker, 2015 |
Spironolactone |
1.29 |
|
Metformin1,3 |
HEK293-OCT2 |
Hacker, 2015 |
Tacrine |
2.3 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Sandoval, 2018 |
Tacrine |
0.4 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
CHO-OCT2 |
Sandoval, 2018 |
Tacrine |
0.6 |
|
Metformin1,3 |
CHO-OCT2 |
Sandoval, 2018 |
Tacrine |
1 |
|
NBD-MTMA |
CHO-OCT2 |
Sandoval, 2018 |
Tacrine |
0.9 |
|
Tetraethylammonium1 |
CHO-OCT2 |
Sandoval, 2018 |
Tamoxifen |
87 |
|
N-methylpyridinium |
HEK293-OCT2 |
Zolk, 2009 |
Telaprevir |
6.4 |
|
1-methyl-4-phenylpyridinium (MPP+) |
HEK293-OCT2 |
Kunze, 2012 |
Tenatoprazole |
20.3 |
|
Metformin1,3 |
HEK293-OCT2 |
Nies, 2011 |
Testosterone |
3 |
|
Not applicable |
N/A |
Koepsell, 2007 |
Tetraethylammonium1 |
77 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Severance, 2017 |
Tetraethylammonium1 |
222 |
|
N-methylpyridinium |
OCT2-expressing oocytes |
Bourdet, 2005 |
Tetraethylammonium1 |
189.2 |
|
N-methylpyridinium |
CHO-OCT2 |
Ming, 2009 |
Tetraethylammonium1 |
110 |
|
NBD-MTMA |
CHO-OCT2 |
Belzer, 2013 |
Tetramethrin |
11.2 |
|
Rhodamine 123 |
HEK293 cells |
Chedik, 2017 |
Tetramethylammonium |
301 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Severance, 2017 |
Tetrapentylammonium |
|
1.5 |
Tetraethylammonium1 |
OCT2-expressing oocytes |
Gorboulev, 1997 |
Topotecan |
61 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
Tramadol |
140.1 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Severance, 2017 |
Triazolam |
65.5 |
|
Tetraethylammonium1 |
S2-OCT2 |
Chiba, 2013 |
Triethylmethylammonium |
125 |
|
NBD-MTMA |
CHO-OCT2 |
Belzer, 2013 |
Trimethoprim |
775 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Belzer, 2013 |
Trimethoprim |
199.2 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Sandoval, 2018 |
Trimethoprim |
14.1 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
CHO-OCT2 |
Sandoval, 2018 |
Trimethoprim |
19.8 |
|
Metformin1,3 |
CHO-OCT2 |
Sandoval, 2018 |
Trimethoprim |
1318 |
|
N-methylpyridinium |
HEK293-OCT2 |
Zolk, 2009 |
Trimethoprim |
113 |
|
NBD-MTMA |
CHO-OCT2 |
Belzer, 2013 |
Trimethoprim |
43 |
|
NBD-MTMA |
CHO-OCT2 |
Sandoval, 2018 |
Trimethoprim |
50.2 |
|
Tetraethylammonium1 |
CHO-OCT2 |
Sandoval, 2018 |
Trimipramine |
0.44 |
|
Metformin1,3 |
HEK293-OCT2 |
Hacker, 2015 |
Tripelennamine |
12.1 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Sandoval, 2018 |
Tripelennamine |
3.7 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
CHO-OCT2 |
Sandoval, 2018 |
Tripelennamine |
2.1 |
|
Metformin1,3 |
CHO-OCT2 |
Sandoval, 2018 |
Tripelennamine |
5.7 |
|
NBD-MTMA |
CHO-OCT2 |
Sandoval, 2018 |
Tripelennamine |
5 |
|
Tetraethylammonium1 |
CHO-OCT2 |
Sandoval, 2018 |
Tropicamide |
691.5 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Sandoval, 2018 |
Tropicamide |
141.4 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
CHO-OCT2 |
Sandoval, 2018 |
Tropicamide |
94.3 |
|
Metformin1,3 |
CHO-OCT2 |
Sandoval, 2018 |
Tropicamide |
189 |
|
NBD-MTMA |
CHO-OCT2 |
Sandoval, 2018 |
Tropicamide |
205.4 |
|
Tetraethylammonium1 |
CHO-OCT2 |
Sandoval, 2018 |
Trospium chloride |
0.07 |
|
Metformin1,3 |
HEK293-OCT2 |
Hacker, 2015 |
Tubocurarine |
78.8 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
Vandetanib |
73.4 |
|
1-methyl-4-phenylpyridinium (MPP+) |
HEK293-OCT2 |
Shen, 2013 |
Vandetanib |
8.8 |
|
Metformin1,3 |
HEK293-OCT2 |
Shen, 2013 |
Vecuronium bromide |
3.5 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
Veliparib |
3913 |
|
1-methyl-4-phenylpyridinium (MPP+) |
HEK293-OCT2 |
Kikuchi, 2013 |
Verapamil |
91.9 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Belzer, 2013 |
Verapamil |
66 |
|
1-methyl-4-phenylpyridinium (MPP+) |
HEK293-OCT2 |
Parvez, 2016 |
Verapamil |
49.7 |
|
1-methyl-4-phenylpyridinium (MPP+) |
CHO-OCT2 |
Sandoval, 2018 |
Verapamil |
4.6 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
CHO-OCT2 |
Sandoval, 2018 |
Verapamil |
20 |
|
Metformin1,3 |
CHO-OCT2 |
Belzer, 2013 |
Verapamil |
36 |
|
Metformin1,3 |
HEK293-OCT2 |
Parvez, 2016 |
Verapamil |
10.3 |
|
Metformin1,3 |
CHO-OCT2 |
Sandoval, 2018 |
Verapamil |
85 |
|
N-methylpyridinium |
HEK293-OCT2 |
Zolk, 2009 |
Verapamil |
21 |
|
NBD-MTMA |
CHO-OCT2 |
Belzer, 2013 |
Verapamil |
9.7 |
|
NBD-MTMA |
CHO-OCT2 |
Sandoval, 2018 |
Verapamil |
21.4 |
|
Para-Aminosalicylic acid (PAS) |
HEK293-OCT2 |
Parvez, 2017 |
Verapamil |
17.8 |
|
Tetraethylammonium1 |
CHO-OCT2 |
Sandoval, 2018 |
Verapamil |
13.4 |
|
YM155 |
HEK293-OCT2 |
Minematsu, 2010 |
YM155 |
15.9 |
|
N-methylpyridinium |
HEK293-OCT2 |
Minematsu, 2010 |
Zafirlukast |
9.7 |
|
4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) |
HEK293-OCT2 |
Wittwer, 2013 |
Zolpidem |
0.15 |
|
Metformin1,3 |
HEK293-OCT2 |
Hacker, 2015 |
The transporters are implicated by in vitro data and/or studies in humans with genetic polymorphisms of the transporter
DDI = Drug Drug Interaction
PK = pharmacokinetic
PD = pharmacodynamic
ND = not determined
NS = not significant
N/A = information not available
Calculation of Fold Change: fold change in the presence of the interacting drug = (value with interacting drug)/(value without interacting drug)
fold change > 1: increase in pharmacokinetic value
fold change < 1: decrease in pharmacokinetic value
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022